Syndax Medical Affairs / Information

Aldoss et al. Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia. Presented at EHA 2025

kmt2a; augment; monotherapy; AUGMENT-101; NCT04065399; relapsed; refractory; acute; leukemia; all; aml